PAR1, but not PAR4, activates human platelets through a G i/o/phosphoinositide-3 kinase signaling axis

Bryan Voss, Joseph N. McLaughlin, Michael Holinstat, Roy Zent, Heidi E. Hamm

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Thrombin-mediated activation of platelets is critical for hemostasis, but the signaling pathways responsible for this process are not completely understood. In addition, signaling within this cascade can also lead to thrombosis. In this study, we have defined a new signaling pathway for the thrombin receptor protease activated receptor-1 (PAR1) in human platelets. We show that PAR1 couples to Gi/o in human platelets and activates phosphoinositide-3 kinase (PI3K). PI3K activation regulates platelet integrin αIIbβ3 activation and platelet aggregation and potentiates the PAR1-mediated increase in intraplatelet calcium concentration. PI3K inhibitors eliminated these effects downstream of PAR1, but they had no effect on PAR4 signaling. This study has identified an important role for the direct activation of Gi/o by PAR1 in human platelets. Given the efficacy of clopidogrel, which blocks the Gi/o-coupled P2Y purinoceptor 12, as an antiplatelet/antithrombotic drug, our data suggest that specifically blocking only PAR1-mediated Gi/o signaling could also be an effective therapeutic approach with the possibility of less unwanted bleeding.

Original languageEnglish (US)
Pages (from-to)1399-1406
Number of pages8
JournalMolecular Pharmacology
Volume71
Issue number5
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

PAR-1 Receptor
1-Phosphatidylinositol 4-Kinase
Blood Platelets
clopidogrel
Platelet Activation
Purinergic P2Y Receptors
Thrombin Receptors
Platelet Aggregation Inhibitors
Hemostasis
Platelet Aggregation
Integrins
Thrombin
Thrombosis
Hemorrhage
Calcium

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

PAR1, but not PAR4, activates human platelets through a G i/o/phosphoinositide-3 kinase signaling axis. / Voss, Bryan; McLaughlin, Joseph N.; Holinstat, Michael; Zent, Roy; Hamm, Heidi E.

In: Molecular Pharmacology, Vol. 71, No. 5, 01.05.2007, p. 1399-1406.

Research output: Contribution to journalArticle

Voss, Bryan ; McLaughlin, Joseph N. ; Holinstat, Michael ; Zent, Roy ; Hamm, Heidi E. / PAR1, but not PAR4, activates human platelets through a G i/o/phosphoinositide-3 kinase signaling axis. In: Molecular Pharmacology. 2007 ; Vol. 71, No. 5. pp. 1399-1406.
@article{e0283f56a0f14b1f8ade4e94b6b6004d,
title = "PAR1, but not PAR4, activates human platelets through a G i/o/phosphoinositide-3 kinase signaling axis",
abstract = "Thrombin-mediated activation of platelets is critical for hemostasis, but the signaling pathways responsible for this process are not completely understood. In addition, signaling within this cascade can also lead to thrombosis. In this study, we have defined a new signaling pathway for the thrombin receptor protease activated receptor-1 (PAR1) in human platelets. We show that PAR1 couples to Gi/o in human platelets and activates phosphoinositide-3 kinase (PI3K). PI3K activation regulates platelet integrin αIIbβ3 activation and platelet aggregation and potentiates the PAR1-mediated increase in intraplatelet calcium concentration. PI3K inhibitors eliminated these effects downstream of PAR1, but they had no effect on PAR4 signaling. This study has identified an important role for the direct activation of Gi/o by PAR1 in human platelets. Given the efficacy of clopidogrel, which blocks the Gi/o-coupled P2Y purinoceptor 12, as an antiplatelet/antithrombotic drug, our data suggest that specifically blocking only PAR1-mediated Gi/o signaling could also be an effective therapeutic approach with the possibility of less unwanted bleeding.",
author = "Bryan Voss and McLaughlin, {Joseph N.} and Michael Holinstat and Roy Zent and Hamm, {Heidi E.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1124/mol.106.033365",
language = "English (US)",
volume = "71",
pages = "1399--1406",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - PAR1, but not PAR4, activates human platelets through a G i/o/phosphoinositide-3 kinase signaling axis

AU - Voss, Bryan

AU - McLaughlin, Joseph N.

AU - Holinstat, Michael

AU - Zent, Roy

AU - Hamm, Heidi E.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Thrombin-mediated activation of platelets is critical for hemostasis, but the signaling pathways responsible for this process are not completely understood. In addition, signaling within this cascade can also lead to thrombosis. In this study, we have defined a new signaling pathway for the thrombin receptor protease activated receptor-1 (PAR1) in human platelets. We show that PAR1 couples to Gi/o in human platelets and activates phosphoinositide-3 kinase (PI3K). PI3K activation regulates platelet integrin αIIbβ3 activation and platelet aggregation and potentiates the PAR1-mediated increase in intraplatelet calcium concentration. PI3K inhibitors eliminated these effects downstream of PAR1, but they had no effect on PAR4 signaling. This study has identified an important role for the direct activation of Gi/o by PAR1 in human platelets. Given the efficacy of clopidogrel, which blocks the Gi/o-coupled P2Y purinoceptor 12, as an antiplatelet/antithrombotic drug, our data suggest that specifically blocking only PAR1-mediated Gi/o signaling could also be an effective therapeutic approach with the possibility of less unwanted bleeding.

AB - Thrombin-mediated activation of platelets is critical for hemostasis, but the signaling pathways responsible for this process are not completely understood. In addition, signaling within this cascade can also lead to thrombosis. In this study, we have defined a new signaling pathway for the thrombin receptor protease activated receptor-1 (PAR1) in human platelets. We show that PAR1 couples to Gi/o in human platelets and activates phosphoinositide-3 kinase (PI3K). PI3K activation regulates platelet integrin αIIbβ3 activation and platelet aggregation and potentiates the PAR1-mediated increase in intraplatelet calcium concentration. PI3K inhibitors eliminated these effects downstream of PAR1, but they had no effect on PAR4 signaling. This study has identified an important role for the direct activation of Gi/o by PAR1 in human platelets. Given the efficacy of clopidogrel, which blocks the Gi/o-coupled P2Y purinoceptor 12, as an antiplatelet/antithrombotic drug, our data suggest that specifically blocking only PAR1-mediated Gi/o signaling could also be an effective therapeutic approach with the possibility of less unwanted bleeding.

UR - http://www.scopus.com/inward/record.url?scp=34247545661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247545661&partnerID=8YFLogxK

U2 - 10.1124/mol.106.033365

DO - 10.1124/mol.106.033365

M3 - Article

C2 - 17303701

AN - SCOPUS:34247545661

VL - 71

SP - 1399

EP - 1406

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -